TNFRSF18 and cancer: Interestingly, it has recently been shown that combined PD-1 blockade and GITR triggering can enhance anti-tumor immunity in murine cancer models, which can be further promoted with chemotherapeutic drugs [59], thus highlighting the potency of GITR stimulation also in combination therapy.